<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C93EEE7C-E578-4F4A-97A8-95989028F2ED"><gtr:id>C93EEE7C-E578-4F4A-97A8-95989028F2ED</gtr:id><gtr:firstName>Ludwig</gtr:firstName><gtr:surname>Neyses</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500025"><gtr:id>7897164A-991B-4B19-8D6F-ADF7BAFA092C</gtr:id><gtr:title>Integrative Physiology of the Plasma Membrane Calcium Pump Isoform 4 in the Healthy and Failing Heart</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500025</gtr:grantReference><gtr:abstractText>Heart failure, which is a condition in which the heart is unable to pump sufficient blood throughout the body, and its early signs are a major cause of disability, reduced quality of life and death in our aging population. In order to develop better treatments we must increase our understanding of the genetic and molecular changes which lead to heart failure. 
Calcium is very important for the correct functioning of the heart and it is well know that disruption of calcium levels leads to cardiovascular complications. One of the proteins involved in the movement of calcium from heart cells is the plasma membrane calcium pump (PMCA); in this project we aim to find out how PMCA regulates the working of the heart. 
Specifically we will generate mice with modified expression of PMCA and determine whether this leads to changes in the structure and/or function of the heart. We use the mouse as a model system as it reflects the human heart and we are able to use tools similar to those used by clinicians to determine how well the heart is working.
This research will improve our understanding of heart failure and may lead to potential new treatment strategies.</gtr:abstractText><gtr:technicalSummary>Heart failure is one of the leading causes of mortality, but our understanding of its pathophysiology and treatment options are limited. Calcium transport anomalies are key aspects in heart failure, but in contrast to several well-characterised transport systems such as Na+-Ca2+ exchanger and SERCA, the role of the plasma membrane calcium pump (or PMCA: Plasma Membrane Calcium / Calmodulin-dependent ATPase), a system which extrudes calcium from the cytoplasm, has remained elusive. The present programme aims at elucidating the role of PMCA4 in the healthy and failing heart. 

In the last 3 years in Manchester, we have achieved a major breakthrough: PMCA is a key signalling molecule, potentially in addition to having a role in relaxation. 

We have shown that:
1. A major isoform, PMCA4b (also known as PMCA4CI), directly interacts with nNOS (neuronal NOS, a regulator of cardiac signalling) through a PDZ domain, tightly downregulates its activity and is tethered to the dystrophin complex via syntrophin. This suggests a role for the PMCA in dystrophin-related cardiac myopathies as well as in common forms of heart failure.
2. PMCA4 also regulates the Ras pathway, which is involved in cardiac hypertrophy and failure. 
3. In contrast to the conventional hypothesis regarding PMCA function, our PMCA4 knock-out mice show enhanced cardiac relaxation, likely mediated by uninhibited nNOS function. 

The present proposal is a direct continuation of this work addressing three questions:
A. What are the molecular and cellular mechanisms of PMCA action in the heart?
We will use electrophysiology of cardiomyocytes from PMCA4 knock-out and over-expressing animals as well as cells transfected with adenoviral constructs to characterise the role of PMCA4 in cardiac calcium transport and relaxation as well as in signalling processes involving Ras, nNOS and syntrophin.
B. What is the physiological function of cardiac PMCA in the whole animal?
Using invasive and non-invasive haemodynamic methods, the cardiac function of our general and heart specific knock-out models will be investigated, a pharmacological approach will determine phenotypic mechanisms. 
C. What is the function of the PMCA in cardiac disease?
The proposed electrophysiological and in vivo studies will be transposed to models of heart disease.

This programme will result in a comprehensive characterisation of PMCA4 function in the heart and potentially identify the PMCA as an attractive target for future drug therapy in heart, and possibly other, diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>867546</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mammalian Genetics Unit</gtr:department><gtr:description>MRC Mammalian Genetics Unit, Harwell</gtr:description><gtr:id>14410B23-FB88-4553-AA45-F0B04907716B</gtr:id><gtr:impact>Partner of EUMODIC consortium, Nature Genetics 2006</gtr:impact><gtr:outcomeId>FEB5C740079-1</gtr:outcomeId><gtr:partnerContribution>Provision of animal models</gtr:partnerContribution><gtr:piContribution>We analysed novel models of disease in mice generated at Harwell with regard to their cardiovascular phenotype</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FD363043-148B-4BEA-8CF1-32DBA3C3D630</gtr:id><gtr:impact>Novel biomarkers for heart failure identified through metabolomics. European Society of Cardiology Congress, Munich Germany. 30th August - 3rd September, 2008/

N/A</gtr:impact><gtr:outcomeId>5C9E7C48247</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>041046F1-AAA0-4F34-A851-990B713A68EA</gtr:id><gtr:impact>The systems biology of the sarcolemmal calcium pump - an approach to identifying a novel drug target European /science Foundation Wellcome Trust Conference, Wellcome Trust Genome Campus, Hinxton, United kingdom 1 - 4th May, 2007

n/a</gtr:impact><gtr:outcomeId>5A0A3FDA112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Chairperson</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>942BB262-69A0-44FF-B2BD-C913D4AA3494</gtr:id><gtr:impact>Frontier Symposium entitled 'Spatial organization signalling pathways in Cardiac myocyes. The XIX World Congress of the International Society for Heart Research - From Cell to Man to Society, Bologna, Italy, 22nd - 26th June, 2007.

N/A</gtr:impact><gtr:outcomeId>FBB3A7529AB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6F3E3B44-3A4D-4B11-AD36-0C670EA77551</gtr:id><gtr:impact>Session entitled: ' New targets for treating HF, Azur-Heart Meeting &amp;quot;Molecular and Cellular Biology of Heart Failure, Carry-le-Rouet, Marseille, France 1 - 3rd June, 2007.

N/A</gtr:impact><gtr:outcomeId>C133FF3A3E4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>01CEA115-8120-4EC3-8CF7-19C5863A5EBF</gtr:id><gtr:impact>Atrial fibrillation and heart failure: are there specific mechanisms and therapeutic targets. European Society of Cardiology 14th - 17th June, Milan Italy, 2007

N/A</gtr:impact><gtr:outcomeId>A9DA5C1916A</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DEF803F6-B8F1-47E9-BEC9-36E5CAA89F9E</gtr:id><gtr:impact>Talk entitled 'Metabolome'. Meeting entitled: La cellule au coeur de l'insuffisance cardiaque&amp;quot; Ecole d'automne de l'institut du thorax, Le Croisic, France 23rd and 24th October, 2008.

N/A</gtr:impact><gtr:outcomeId>7863BD6DF31</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F0E87C70-7027-4C52-A075-23785FEAC2EA</gtr:id><gtr:impact>Deutsche Gesellschaft fur Inere Medizin Wiesbaden, Germany. 29th - 2nd April, 2008. Invited talk. &amp;quot;The UK Health System&amp;quot; and &amp;quot;Going Abroad as a Clinician Scientist&amp;quot;

N/A</gtr:impact><gtr:outcomeId>1CE32F24656</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4C3C7F40-D4F1-443E-A617-E1EE30E5A9E5</gtr:id><gtr:impact>PRIME: The role of mice in medical research. Talk given to research charity leaders, patient group leaders.

N/A</gtr:impact><gtr:outcomeId>148FF0AF4AC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>18B1AF33-6260-4B0C-B2FE-98360D43DCA7</gtr:id><gtr:impact>Workshop III: ca2+ pumps and exchangers. Session title: Signalling by the sarcolemmal calcium pump. XIV International Symposium Calcium Binding Canary Islands, 16th - 21st October, 2007

N/A</gtr:impact><gtr:outcomeId>18F396E1658</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F9623A9-70B5-4AF0-84C7-DD19A451C0DC</gtr:id><gtr:impact>Session entitled: 'Beyond CA2+ Pumps', Life Sciences Meeting, Glasgow 8 - 12th July, 2007

N/A</gtr:impact><gtr:outcomeId>D3D11BEB16C</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>59EBA154-414C-4152-B0D2-0CA63B402371</gtr:id><gtr:impact>The Heart. Keystage1 and keystage2 Infant and Junior School children

N/A</gtr:impact><gtr:outcomeId>E1913F2C5E2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>310000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU FP6 Integrated Proj</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>7D1D9692-D127-4D90-811A-3A4D7E6AFEEE</gtr:id><gtr:outcomeId>0A00F5F63850</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (G0802004 The sarcolemmal calcium signalling protein PMCA4. A novel target to reduce cardiac hypertrophy and failure)</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7C35A1E9-FC60-41D1-8F4A-1D555DD70CAA</gtr:id><gtr:outcomeId>5373DEE6FB40</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Heart Foundation Generation and initial characterization of a conditional cardiac specific gene deletion of the sarcolemmal calcium pump (PMCA1).</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>EF5F51A6-7B68-4DDD-8F46-F90DE3D47C72</gtr:id><gtr:outcomeId>cBNU7FtxqXe0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification and evaluation of novel serum biomarkers for heart failure using metabolics - an initial step towards an holistic view of heart failure/Central Manchester University Hospital Foundation Trust</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7C0CD9C2-87B8-472E-90E6-1CED903457EA</gtr:id><gtr:outcomeId>gZA7D6fp9Sj0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>PMCA4 knockout mouse line. Generated by homologous recombination in ES cells (see Schuh et al 2004). Mouse line has been generated and characerised in terms of male fertility phenotype, this data is publically available. Characterisation of cardiac phenotype is ongoing. Took 2.5 years to develop and establish the PCA4 knock-ut line. 2 years to chracterise male fertility phenotype.</gtr:description><gtr:id>146C1B2A-8D0D-4106-A0DB-25B5F86C8D67</gtr:id><gtr:impact>GIVEN TO 5 RESEARCH GROUPS</gtr:impact><gtr:outcomeId>496584C93E8</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PMCA4 KO</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Transgenic mouse overexpressing PMCA4 specifically in the heart. Mouse line has been generated and characterised (see Oceandy et al 2007).</gtr:description><gtr:id>81E6533D-FC94-42A8-A562-A77474A8BA41</gtr:id><gtr:impact>Transgenic mouse overexpressing PMCA4 specifically in the heart. Mouse line has been generated and characterised (see Oceandy et al 2007).</gtr:impact><gtr:outcomeId>058D0790D0C</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PMCA4 TG</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>27BDD0C3-8183-4726-8238-C71590FA5F41</gtr:id><gtr:title>Physiological implications of the interaction between the plasma membrane calcium pump and nNOS.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5082d72d197846975ebcb9553432d32"><gtr:id>e5082d72d197846975ebcb9553432d32</gtr:id><gtr:otherNames>Cartwright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>4EBF26C1299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FD02350-D9F1-4D1C-891E-AC4FB16045E3</gtr:id><gtr:title>The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c64fb0ed5e9e0c15be053aa531782b03"><gtr:id>c64fb0ed5e9e0c15be053aa531782b03</gtr:id><gtr:otherNames>Williams JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>0C53D2D0920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB280F2C-B2BA-4A91-AA09-41E039D39A11</gtr:id><gtr:title>Plasma membrane calcium ATPase and its relationship to nitric oxide signaling in the heart.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5082d72d197846975ebcb9553432d32"><gtr:id>e5082d72d197846975ebcb9553432d32</gtr:id><gtr:otherNames>Cartwright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>99762CC084A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CACFF5B-EA60-4C57-B4BE-108256A2A736</gtr:id><gtr:title>Inhibition of nuclear import of calcineurin prevents myocardial hypertrophy.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f40c434bff32337c10bbc55ef6872c06"><gtr:id>f40c434bff32337c10bbc55ef6872c06</gtr:id><gtr:otherNames>Hallhuber M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>10FC889385E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00A63436-39A1-4D3C-B2B3-77035BE1D078</gtr:id><gtr:title>Development and characterization of a novel fluorescent indicator protein PMCA4-GCaMP2 in cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn><gtr:outcomeId>pm_14950_20_23880607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>010F6DDE-4F32-4279-9CDE-51074D835F84</gtr:id><gtr:title>Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14950_20_21965681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9343CA29-72EE-4064-BC4F-49D1F6937611</gtr:id><gtr:title>The interaction between endogenous calcineurin and the plasma membrane calcium-dependent ATPase is isoform specific in breast cancer cells.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9772ee5f2688407a41dea655589c3af9"><gtr:id>9772ee5f2688407a41dea655589c3af9</gtr:id><gtr:otherNames>Holton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>E4B796A2893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>255651BB-EFE8-4C52-A655-D20F3741C316</gtr:id><gtr:title>The emergence of plasma membrane calcium pump as a novel therapeutic target for heart disease.</gtr:title><gtr:parentPublicationTitle>Mini reviews in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1389-5575</gtr:issn><gtr:outcomeId>10E208B77C7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1DB9EF7-AC7C-437E-8F98-E1B4F113923B</gtr:id><gtr:title>Targeting the sarcolemmal calcium pump: a potential novel strategy for the treatment of cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Cardiovascular &amp; hematological agents in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1871-5257</gtr:issn><gtr:outcomeId>0053B729BEC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0446117-347A-4C66-959F-03FDB90EA5A2</gtr:id><gtr:title>Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>F7C9593C68D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7533F6F-679F-4C98-A1EB-DE3767FD9DA6</gtr:id><gtr:title>Sperm phenotype of mice carrying a gene deletion for the plasma membrane calcium/calmodulin dependent ATPase 4.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/836e99ca669c23f460d3cf0f154c6686"><gtr:id>836e99ca669c23f460d3cf0f154c6686</gtr:id><gtr:otherNames>Withers S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>4D674225076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>950E6BB1-6168-4E9D-8AA2-BA26EACCF4D9</gtr:id><gtr:title>The regulatory function of plasma-membrane Ca(2+)-ATPase (PMCA) in the heart.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>B9E61796E8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7B17C04-7CB5-470A-AA97-AEA04DC5872D</gtr:id><gtr:title>Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardium.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>71889FE7207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCFFAECE-5881-416E-B9A6-293801A31455</gtr:id><gtr:title>Local signals with global impacts and clinical implications: lessons from the plasma membrane calcium pump (PMCA4).</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>oGejkmA9jWk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E38CC4D0-2B42-4A55-B8A1-C26B3AF4D4E8</gtr:id><gtr:title>Plasma membrane calcium ATPase isoform 4 inhibits vascular endothelial growth factor-mediated angiogenesis through interaction with calcineurin.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5a2205be0823bf4a0d59146c0b92f6"><gtr:id>cd5a2205be0823bf4a0d59146c0b92f6</gtr:id><gtr:otherNames>Baggott RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>5460954a92f3f1.85923878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49389344-4962-4E7B-B982-7DFE7B94A3A3</gtr:id><gtr:title>Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>73EEE898C08</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A4FE69D-4F6B-408C-894B-65B6C266147E</gtr:id><gtr:title>Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14bc14b523f46259b756e82875d7f82"><gtr:id>c14bc14b523f46259b756e82875d7f82</gtr:id><gtr:otherNames>Liu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>qp3Y7FDSS9g</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500025</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>